Personnalisez votre veille

Inscrivez-vous gratuitement.

Espace publicitaire · 728×90

Chutes & Ladders—Former Roche oncology head turns to Tubulis

Just a moment... • Publié le 10 janvier 2026

After netting a $361 million series C funding round in October, 2024 Fierce 15 winner Tubulis has reeled in a big name for its chief medical officer spot in Charles Fuchs, M.D. Fuchs is a world-renowned oncology expert who split from Roche last month after five years of service as the company’s SVP and global head of oncology and hematology product development.

Espace publicitaire · 300×250

Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround

Quanterix has a new chief executive and president in Everett Cunningham, but analysts at Leerink see Illumina’s former commercial chief facing an uphill battle in his bid to turn the medtech’s fortunes around.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Illumina hires former NHGRI Director Eric Green as new chief medical officer

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute, Eric Green, M.D., Ph.D., will now step into the commercial life sciences world as the new chief medical officer of Illumina.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

1st biotech IPO of 2026 sees Aktis bring in $318M via upsized offering

Aktis Oncology exceeded its own expectations for its IPO in a good omen for those hoping for a more inviting public market this year.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug

Parabiosis Medicines raises $305 million to upend the status quo Biotech startup Parabiosis Medicines has raised $305 million in a Series A financing round led by ARCH Venture Partners, with participation from Perceptive Advisors and…

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Lilly buys inflammation biotech Ventyx for $1.2B in wake of Parkinson's, CV readouts

Ventyx has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape

Alveus Therapeutics, which launched Thursday under the stewardship of former I-Mab CEO Raj Kannan, is hoping its development candidates can overcome pitfalls common to existing obesity medicines.

style youtuber•1 janvier 1970

🇬🇧 → 🇫🇷

Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential

Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.

style youtuber•1 janvier 1970

Personnalisez votre veille

Articles similaires

Quanterix nabs Illumina’s CCO as new leader, but Leerink warns of ‘significant lift’ needed for turnaround

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

Illumina hires former NHGRI Director Eric Green as new chief medical officer

1st biotech IPO of 2026 sees Aktis bring in $318M via upsized offering

Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug

Lilly buys inflammation biotech Ventyx for $1.2B in wake of Parkinson's, CV readouts

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape

Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential